Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.36)
# 4,288
Out of 5,129 analysts
17
Total ratings
26.67%
Success rate
-24.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.37 | +701.07% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.73 | +824.86% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $0.53 | +1,605.51% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $4.18 | +91.39% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $29.34 | +240.83% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.42 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $3,750 | $3.03 | +123,662.38% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $0.92 | +1,530.43% | 1 | Jun 29, 2023 | |
| ATYR aTyr Pharma | Reinstates: Buy | $9 | $0.88 | +922.73% | 1 | Mar 6, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.20 | +856.28% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $90 | $57.28 | +57.12% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.31 | +13,319.91% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $1.69 | +1,988,065.68% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.37
Upside: +701.07%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.73
Upside: +824.86%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $0.53
Upside: +1,605.51%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $4.18
Upside: +91.39%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $29.34
Upside: +240.83%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.42
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $3,750
Current: $3.03
Upside: +123,662.38%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $0.92
Upside: +1,530.43%
aTyr Pharma
Mar 6, 2023
Reinstates: Buy
Price Target: $9
Current: $0.88
Upside: +922.73%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.20
Upside: +856.28%
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $57.28
Upside: +57.12%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.31
Upside: +13,319.91%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $1.69
Upside: +1,988,065.68%